• Lantern Pharma has publicly launched predictBBB.ai (TM), its AI-driven module for predicting small-molecule blood-brain barrier permeability.
• The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning.
• Powered by Lantern’s vast molecular features data lake and ensemble algorithms, the platform sets a new computational benchmark for CNS drug discovery.
• Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach.
• The tool is publicly accessible through a freemium model, aiming to drive adoption, strategic partnerships, and accelerate CNS therapeutic development.
• Lantern Pharma subsidiary Starlight Therapeutics secures FDA IND clearance for its Phase Ib/IIa trial combining STAR-001 (“LP-184”) and spironolactone in recurrent glioblastoma multiforme.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has introduced predictBBB.ai(TM), a publicly available AI module designed to predict blood-brain barrier (“BBB”) permeability for small-molecule drugs with unprecedented speed and accuracy (https://ibn.fm/9RZYo).

Crossing the BBB remains one of the pharmaceutical industry’s most persistent challenges. Traditionally, only 2-6% of small molecules manage to penetrate this critical barrier. Lantern Pharma aims to transform this bottleneck by providing researchers with real-time predictions powered by billions of molecular data points drawn from its proprietary molecular features data lake.

The module’s performance metrics speak for themselves: 94% accuracy, 95% sensitivity, and 89% specificity, all achieved through an ensemble of machine learning models including logistic regression, random forests, SVMs, and deep neural networks.

By claiming five of the top eleven slots on the Therapeutic Data Commons leaderboard, Lantern Pharma demonstrates clear technological superiority over academic and commercial competitors.

Lantern is offering predictBBB.ai(TM) via a freemium model, granting open access to foundational BBB prediction tools while positioning more advanced functionality for partnership-driven deployment. This strategy aims to foster early adoption among pharma and academia, leading to longer-term collaborations.

“We’re witnessing unprecedented demand for AI-driven solutions that deliver measurable impact on pharmaceutical development success rates,” said Panna Sharma, Chief Executive Officer of Lantern Pharma. “Our BBB prediction module establishes the foundation for deeper partnerships that leverage our comprehensive platform capabilities to accelerate therapeutic development across diverse disease areas while maintaining the highest standards of scientific rigor and predictive accuracy.”

The module’s architecture is built on real-time processing of SMILES molecular input via ensemble algorithms, underpinned by advanced feature engineering and synthetic data augmentation. Lantern plans to expand its suite of AI modules to cover a wider range of drug development properties, leveraging the same robust data and architecture. Predicting BBB permeability early can significantly reduce costly failures in CNS drug development, where failure rates and costs remain critically high. Lantern’s tool could lower risk and timeline for brain cancer and neurological therapies 

“This public release has the potential to be a paradigm shift in how pharmaceutical organizations and researchers approach CNS drug development,” Sharma added. “Our technology transforms what has historically been one of drug discovery’s critical bottlenecks into a competitive advantage. By democratizing access to industry-leading BBB prediction capabilities through our freemium approach, we’re enabling researchers worldwide to accelerate therapeutic development while building strategic partnerships that drive innovation.”

The release aligns with Lantern’s broader RADR(R) AI platform, which integrates this BBB module alongside other predictive tools for molecular and clinical performance, collectively enabling more efficient therapeutic development, especially in CNS and oncology domains.

Complementing this technological advance, Lantern Pharma’s subsidiary Starlight Therapeutics secured Food and Drug Administration IND (investigational new drug) clearance for its Phase Ib/IIa trial combining STAR-001 (“LP-184”) and spironolactone in recurrent glioblastoma multiforme (“GBM”); a study enabled by Lantern’s AI-driven RADR(R) platform (https://ibn.fm/PScS6). The company is currently undergoing a Phase Ia trial to determine dosing, safety, and the maximum tolerated dose across various solid tumors, including GBM.

Starlight is planning to initiate the Phase Ib/IIa trial between late 2025 and early 2026, with the goal of assessing the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with recurrent GBM.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• IzoView Breast CT targets aggressive market displacement with up to 67% lower pricing than competing breast CT systems, positioning at $500K versus competitors priced up to $1.5 million
• True 360-degree 3D imaging without compression positioned to bridge the clinical gap between standard screening and MRI, offering 100x greater spatial resolution than MRI at significantly lower cost
• Platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades, creating scalable revenue expansion without hardware replacement

Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast tissue. Dense breast tissue creates a fundamental imaging challenge in compression-based imaging, like mammography, where overlapping structures can mask cancers, potentially delaying diagnosis when cancers are small and in their most treatable stages. This limitation represents an $8 billion annual burden in follow-up procedures, repeat imaging, and unnecessary interventions driven by inconclusive results from current screening technologies.

The breast imaging landscape has remained largely static for decades, dominated by compression-based mammographic systems never designed specifically for breast cancer the detection requirements of half of women undergoing screenings. While digital enhancements like tomosynthesis have provided incremental improvements, the fundamental constraints of 2D imaging and breast compression continue to limit diagnostic confidence, particularly in dense tissue cases.

This technological plateau occurs against rapidly advancing computational capabilities, artificial intelligence integration, and precision manufacturing that enable entirely new approaches to medical imaging. Current diagnostic pathways often require multiple imaging modalities, callback procedures, and complex workflows that consume significant resources while potentially delaying definitive diagnosis.

Izotropic (CSE: IZO) (OTCQB: IZOZF) is developing this type of transformational approach through its IzoView Breast CT Imaging System, designed to disrupt established imaging categories through projected superior clinical performance at competitive pricing.

Competitive Positioning Targets Market Displacement

Izotropic’s strategic positioning reflects sophisticated understanding of how disruptive medical technologies achieve market penetration. As Tomosynthesis (“DBT”) is becoming increasingly popular for screening, IzoView works alongside DBT, with its images read in conjunction with DBT scans, to serve higher-value segments such as dense breast imaging, where cancer risk is elevated and current technologies fall short.

The competitive analysis reveals significant pricing advantages over existing breast CT systems. With competing devices priced up to USD $1.5M, IzoView’s target price of $500K represents up to a 67% cost reduction that could accelerate adoption across imaging centers previously priced out of breast CT technology.

This pricing strategy positions IzoView to potentially displace multiple existing technologies simultaneously. The device targets replacement opportunities in ultrasound systems ($200K-$300K), contrast-enhanced mammography (~$420K), automated breast ultrasound ($200K-$300K), and molecular breast imaging (~$600K), while offering clinical capabilities approaching breast MRI performance at a fraction of the cost.

The clinical differentiation centers on IzoView’s true 360-degree 3D imaging capability without breast compression. Unlike tomosynthesis, which provides limited-angle 3D reconstruction, IzoView images the breast in its natural state with complete three-dimensional visualization. This approach eliminates tissue overlap masking while providing 100x greater spatial resolution than MRI systems.

The 10-second imaging session offers substantial workflow advantages over MRI (60+ minutes) while maintaining radiation doses comparable to 2-view mammography.

Platform Architecture Enables Scalable Value Creation

IzoView’s design as an upgradeable platform rather than a fixed-function device creates multiple value creation opportunities extending beyond initial capital equipment sales. The company has identified 14 potential future indications for IzoView in its current form, across five clinical areas: screening, diagnosis, monitoring, treatment planning, and personalized medicine.

This platform approach enables advanced capabilities delivery through software updates rather than hardware replacement, creating strong retention incentives for early adopters while generating recurring revenue opportunities. Healthcare facilities investing in IzoView can expand imaging capabilities over time without additional capital expenditure for core system replacement.

The modular engineering addresses practical deployment considerations that have limited competing breast CT system adoption. IzoView incorporates radiation self-shielding, eliminating specialized facility requirements that add installation cost and complexity. The patient-centered design focuses on comfort and accessibility, addressing common patient experience limitations with existing breast imaging technologies.

Izotropic’s exclusive worldwide licensing agreement with the Regents of the University of California provides foundational technology, while the developing patent portfolio focuses on integrated capabilities including image acquisition, data presentation, workflow integration, and artificial intelligence applications. Trade secret elements, including a proprietary deep machine learning image reconstruction algorithm provide additional competitive protection. 

Market Dynamics Support Disruptive Technology Adoption

The global breast imaging device market’s projected growth from $5.4 billion in 2024 to $8.69 billion by 2030, representing an 8.25% compound annual growth rate (“CAGR”). The U.S. market alone is forecasted to expand from $1.0 billion to $1.55 billion during the same period (7.57% CAGR). This growth is being driven by increased demand for advanced diagnostic capabilities, particularly in dense breast imaging applications, as well as rapid adoption of high-growth modalities such as digital breast tomosynthesis, molecular breast imaging, and breast MRI.

IzoView’s initial indication as an adjunct to tomosynthesis with contrast enhancement for dense breast screening in asymptomatic women positions the device to capture share from multiple existing categories while helping define the emerging next-generation breast imaging segment. This positioning addresses both clinical limitations and economic inefficiencies in current diagnostic pathways.

The economic value proposition addresses healthcare system cost pressures through potential consolidation of multi-step diagnostic workflows. Current pathways often require sequential imaging across multiple modalities (e.g., initial mammography, followed by tomosynthesis, ultrasound, and potentially MRI), each adding cost, time, and patient anxiety. IzoView’s comprehensive imaging capability in a single session could eliminate many sequential steps while providing superior diagnostic information.

The device’s positioning between tomosynthesis and MRI in both clinical capability and cost structure creates market opportunities across imaging centers that currently cannot justify MRI investments but require enhanced diagnostic capabilities beyond conventional mammography. This accessibility could drive rapid adoption across diverse healthcare environments.

Izotropic’s regulatory preparation includes FDA pathway clinical study design alignment, providing clear direction for pivotal study execution and market authorization. The completion of comprehensive business planning and financial modeling demonstrates preparation for post-approval market entry, while market education initiatives recognize that breakthrough medical technologies require awareness building alongside regulatory approval.

Transformational Potential at Market Inflection Point

Izotropic’s development of IzoView positions the company at the convergence of favorable market dynamics: growing demand for enhanced breast imaging, technological capabilities enabling superior diagnostic approaches, and economic pressures favoring comprehensive single-modality solutions over multi-step diagnostic pathways.

The combination of significant clinical advantages, competitive pricing, platform scalability, and comprehensive commercialization preparation creates a foundation for potentially transformational market impact. IzoView could establish a new standard for how breast cancer detection integrates advanced imaging technology with practical healthcare delivery requirements.

For more information, visit the company’s website at www.IzoCorp.com

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

Informa, a company on a mission to provide professionals and commercial customers with access to extraordinary people and exceptional insights, is proud to announce FinovateFall, coming this September. The industry-leading event will deliver cutting-edge fintech demos, expert insights, and offer high-impact networking opportunities. Held at The Marriott Marquis Times Square, New York, this event will provide attendees with the opportunity to discover innovative fintech solutions that banks can utilize today, while connecting with senior-level experts who can help them plan for the future.

FinovateFall will feature a number of themes, including payments, open banking, anti-fraud and security, financial inclusion, SME/SMB banking, cryptocurrencies, and stablecoins. It is estimated that over 2,000 senior decision-makers, 1,000 banks and investors, and 475 financial institutions, will be in attendance, making it the go-to event for anyone in this space or with an interest in learning more about this industry.

Some of the speakers at the event will include Michelle Tran, Founder of NYC Fintech Women; Sarah Biller, Co-Founder of Fintech Sandbox; Sherry Wu, CTO at the University of Michigan Credit Union; and Pam Hannett, VP at Liberty Bank. There will also be a keynote address by Beth Haddock, a Board Member and Global Policy Lead at stablecoin Standard, discussing how stablecoins are poised to reshape banking in 2025.

In addition, the event will also announce the winners of the Finovate Awards on September 9, 2025. The awards recognize the fintech industry and its companies that are driving innovation in the fintech sector. It celebrates individuals who have been at the forefront of bringing new ideas to life. In total, 30 individuals in fields such as alternative investing, financial inclusion, UX/CX, lending, and payments, will be crowned.

Some of the judges at this year’s Finovate Awards include Shelley Pittman, a Partner at Advintro; Pradeep Muthukamatchi, a Principal Cloud Architect at Microsoft; Mary Wisniewski, an Editor-at-large at Cornerstone Advisors; and Jim Perry, a Senior Strategist at Market Insights.

To learn more about FinovateFall, please visit https://informaconnect.com/finovatefall

To learn more about Finovate Awards, please visit https://ibn.fm/yMuE6

• 50% joint venture interest in Ambler Metals, which controls Alaska’s high-grade Upper Kobuk Mineral Projects in one of the richest copper-dominant districts globally
• $24.6 million in cash as of May 31, 2025, with Base Shelf Prospectus and $25 million ATM Program in place for future funding flexibility
• Ongoing development of Arctic and Bornite deposits, backed by agreements with local Alaska Native Corporation for collaborative exploration

Copper’s Strategic Role in Energy Transition

Global demand for copper is set to rise sharply over the next decade as electrification, grid modernization, and renewable energy accelerate. The International Energy Agency estimates that copper demand from clean energy technologies will more than double by 2040, driven by upgraded transmission infrastructure, and the buildout of electric vehicles, and wind and solar capacity.

With many of the world’s producing copper mines facing declining grades, exploration and development projects in stable jurisdictions are increasingly critical to meeting long-term supply needs. This dynamic places high-grade, North American copper districts like Alaska’s Ambler Mining District in a favorable position to attract investment and development capital.

A High-Grade, Copper-Dominant District

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) holds a 50% interest in Ambler Metals LLC, a joint venture with South32 Limited, a globally diversified mining company. Ambler Metals owns 100% of the Upper Kobuk Mineral Projects (“UKMP”) in northwestern Alaska’s Ambler Mining District, a region recognized as one of the richest and most prospective copper-dominant areas globally.

The UKMP hosts both polymetallic volcanogenic massive sulphide (“VMS”) deposits, containing copper, zinc, lead, gold, and silver, and carbonate replacement deposits with high-grade copper and cobalt mineralization. The company’s primary development focus is on the Arctic VMS deposit and its exploration focus is on the Bornite carbonate replacement deposit.

The Arctic deposit features a feasibility-level resource, while Bornite contains a preliminary-economic-assessment-level resource with substantial growth potential for critical minerals. Together, they form the foundation of Trilogy’s long-term strategy to develop the Ambler Mining District into a premier North American copper producer.

Collaborative Approach with Local Stakeholders

An agreement with NANA Regional Corporation, Inc., an Alaska Native Corporation, provides a framework for exploration and potential development in cooperation with local communities. This partnership approach helps ensure that project development respects subsistence livelihoods while delivering economic benefits to the region.

Strong Balance Sheet and Flexible Funding Options

As of May 31, 2025, Trilogy reported $24.6 million in cash and $23.8 million in working capital – sufficient to fund its approved fiscal 2025 cash budget of $3.1 million.

In April 2025, the company filed a Base Shelf Prospectus in Canada and a corresponding shelf registration statement on Form S-3 in the U.S., allowing for the issuance of up to $50 million in various securities over the next two to three years.

On May 27, 2025, Trilogy announced the launch of an at-the-market equity program (ATM Program), enabling it to sell up to $25 million in common shares at prevailing market prices. Proceeds, if utilized, are expected to support the continued development of the UKMP and general corporate purposes.

Advancing Key Projects

Earlier this year, Trilogy completed the Bornite Preliminary Economic Assessment (“PEA”). The study delivered initial economics for the underground portion of the high-grade copper-cobalt deposit, demonstrating the potential for a 30-year mine-life when combining Arctic and Bornite.

While there has been a reduction in overall activities at the State of Alaska’s Ambler access project, a planned 211-mile road to connect the mining district to Alaska’s highway system, Trilogy and its partners continue to advance technical work on the core deposits in anticipation of future infrastructure solutions.

Well-Positioned for Copper Market Dynamics

With a 50% interest in one of North America’s richest undeveloped copper districts, Trilogy Metals is strategically positioned to benefit from tightening copper supply-demand fundamentals. Its high-grade resources, stable jurisdiction, and strong joint venture partnership provide a solid foundation for future development.

The company’s prudent cash management, combined with flexible capital-raising tools through its Base Shelf Prospectus and ATM Program, enhances its ability to fund project advancement while minimizing dilution.

As the global energy transition continues to reshape commodity markets, the combination of grade, jurisdiction, and scale at the Upper Kobuk Mineral Projects underscores Trilogy’s potential role in meeting the world’s growing copper needs.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at ibn.fm/TMQ

• The company’s AI-powered explosives detection technology, SpotlightAI(TM), has processed over 1.78 million drone images in Ukraine, detecting more than 31,600 explosive threats.
• The company holds a U.S. patent valid until 2043, with protections extending to 47 jurisdictions through national phase filings.
• Safe Pro’s AI threat detection will participate in two events of the U.S. Army’s 2026 Concept Focused Warfighter Experiment (“CFWE”).
• The Senate has advanced an additional $617 million in potential funding for small unmanned aircraft systems, a category that Safe Pro’s technology supports.
• Expanding patent protections and military validation is expected to strengthen the company’s long-term position in the defense and humanitarian demining markets.

Safe Pro Group (NASDAQ: SPAI), an emerging provider of AI-powered security and threat detection solutions, is taking a significant step in its intellectual property strategy, expanding international patent protections for its AI-powered explosives detection systems. The company has received publication notices under the Patent Cooperation Treaty for applications in Australia, Israel, and the European region, signaling progress in securing exclusive rights across multiple jurisdictions (https://ibn.fm/HjwrB).

The publication stage places competitors on notice that similar technology development could lead to infringement claims. Safe Pro’s patent strategy is aimed at long-term shareholder value, according to Chairman and CEO Dan Erdberg. He noted that the global landmine crisis is intensifying, especially as some European nations reconsider their participation in the Ottawa Convention, which bans anti-personnel mines, and that may lead to a dramatic increase in threats to armed forces and allies.

“Landmines are already a global problem, and their further proliferation poses a massive challenge. Therefore, we are actively pursuing global protection of our valuable intellectual property, which has demonstrated its real-world ability to uniquely address this threat,” Erdberg said.

Safe Pro’s U.S. Patent No. 12,146,729, granted earlier this year, covers autonomous detection, identification, and labeling of explosives in orthomosaic images derived from drone footage. The patent runs until 2043 and supports applications across defense, humanitarian demining, and other sectors. The company has filed national phase applications in Europe, Canada, Australia, New Zealand, Japan, Israel, and Ukraine, ultimately covering 47 jurisdictions.

The company’s SPOTD (Safe Pro Object Threat Detection) system is designed to detect over 150 types of small explosive threats, including landmines and unexploded ordnance. The technology can be deployed either on the edge for real-time use (SpotlightAI(TM) OnSite) or through Amazon Web Services for cloud-based operations.

The datasets underpinning the AI’s accuracy are substantial. In Ukraine, SpotlightAI(TM) has processed more than 1.78 million high-resolution drone images, identifying over 31,600 explosive threats across nearly 7,819 hectares; an area comparable to the size of Manhattan. This volume of real-world operational data strengthens both the system’s credibility and its market potential.

The U.S. Army has recognized the capability of Safe Pro’s AI. The company will participate in two events at the 2026 Concept Focused Warfighter Experiment: the Maneuver demonstration and the Live Breach event. These events are part of the Army Futures Command’s initiative to evaluate emerging technologies for battlefield use (https://ibn.fm/UBh99).

During these events, Safe Pro will showcase how its AI can detect and identify threats in a fraction of a second per image, providing rapid situational awareness. The company is also working to integrate its technology into the TAK (Tactical Assault Kit) ecosystem, enabling near-instant transmission of detections to soldier-carried or vehicle-mounted devices.

This integration into widely used military software platforms could make Safe Pro’s technology a standard tool for small unit operations. The timing aligns with increased U.S. defense budget allocations for drone and AI capabilities. The Senate Appropriations Committee has advanced a proposal for $617 million in funding for small unmanned aircraft systems, including the Short Range Reconnaissance program, which aligns with Safe Pro’s operational focus. Additionally, the One Big Beautiful Bill Act allocates up to $30 billion for drones, AI, and defense modernization.

With the humanitarian and commercial demining market also expanding, as nearly 60 countries are affected by landmines or unexploded ordnance, Safe Pro’s addressable market extends beyond defense to reconstruction and infrastructure development. The technology’s adaptability to multiple deployment methods enhances its relevance in varied operational settings.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

In a sign of its enduring relevance and demand, Sustain SoCal will host the 10th annual Water Solutions conference this month, marking a decade of delivering important insights regarding the use, reuse, and sustainability of one of the world’s most critical resources.

Water Solutions 10 will help resource managers explore the latest strategies for water capture, storage, groundwater replenishing, and combatting contamination, among other important issues. At Sustain SoCa’ls Water Solutions 5 event, the organization partnered with the California Data Collaborative. With a nod to that event, Water Solutions 10 will explore today’s solution portfolio with added emphasis on data and AI applications. Cybersecurity will also be a major point of focus as multiple Chief Innovation Security Officers (“CISO”) are set to speak and be in attendance.

The conference will address regional collaborations and policy efforts as a means to ensure the supply of water throughout Southern California. Affordability will be a major talking point as speakers examine case studies in water importation, groundwater rights, reuse, desalination projects, and more. The agenda has not yet been fully developed, but attendees can anticipate solutions that explore recycling, distribution, anti-contamination efforts such as PFAS mitigation, stormwater capture, hydrogen power, and wastewater innovation.

Key aspects of the event will include:

• Notable speakers addressing trends in water use and strategies for future sustainability.
• Opportunities to network with peers and influencers concerned about the state of California’s water resources.
• Real world applications of the materials discussed.
• Information-based interaction with guest luminaries to build a deeper understanding of resource reality, the nuances of the regulatory landscape, and cutting-edge best practices.

The event will take place Tuesday, Aug. 26 in Irvine, California, at the University of California’s UCI Beall Applied Innovation Center. Past years’ Water Solutions events have explored themes such as “Applications of AI Advanced Data Modeling: Water Treatment & Distribution,” “The Water-Hydrogen Nexus,” “Predicting Atmospheric Rivers: A Path toward FIRO,” and “Efficiency and Innovation in Irrigation.”

Sustain SoCal has a long history of exploring and implementing pragmatic solutions to the real-world challenges created by growth, change and inefficiency throughout Southern California. The organization conducts conferences, workshops, and networking events, all geared to helping share pertinent knowledge and ensuring economically impactful progress.

Registration is open now! Further logistical, speaker, and agenda details for “Water Solutions 10” are available at https://sustainsocal.org/event/water-solutions-10.

• AI platform can detect over 150 types of explosive threats in real time, with over 1.78 million drone images processed and 31,600 threats identified in Ukraine operations.
• Integration into U.S. Army’s ATAK system for intelligence sharing could enable broad deployment across numerous military devices.
• Safe Pro’s scalable technology has applications across defense, humanitarian, and commercial sectors.

Safe Pro Group (NASDAQ: SPAI), an emerging provider of AI-powered security and threat detection solutions, has integrated its drone-based object detection capabilities with various Drone platforms currently utilized by the U.S. Army. The company’s computer vision software, developed over the course of more than eight years, is designed to rapidly identify landmines and unexploded ordnance (“UXO”) with high precision, even when using commercially available drone platforms (https://ibn.fm/bTccg).

This development follows Safe Pro’s multi-year operational work in Ukraine, where its AI detection technology has analyzed over 1.78 million drone images and identified more than 31,600 explosive threats across a combat zone equivalent in size to Manhattan.

A powerful demonstration video released by the company (https://ibn.fm/iUNUG) shows its AI at work in Ukraine, highlighting detection capabilities designed to improve convoy protection, route planning, and situational awareness in conflict zones. The company’s SPOTD (Safe Pro Object Threat Detection) technology is capable of identifying more than 150 types of explosive devices, including anti-personnel mines and plastic munitions smaller than a soda can, in a fraction of a second per image.

Powered by real-time detection artificial intelligence and machine learning models and novel algorithms, Safe Pro AI’s patented AI technology rapidly identifies and maps landmines and explosive threats in real time, delivering real world results for customers demanding the ground truth.

Safe Pro’s AI-powered system is drone-agnostic, allowing users to deploy its software on basic, commercially available drones. This makes it particularly relevant for military units that need agile and cost-effective ISR (intelligence, surveillance, and reconnaissance) capabilities.

The company’s Safe Pro Object Threat Detection (“SPOTD”) technology has been tested in environments that mimic real-world battlefield conditions, where it delivers rapid mapping and detection of hazards that would otherwise endanger personnel. This functionality supports the U.S. Army’s need for next-generation drone-based reconnaissance tools as part of its SRR program, designed to modernize battlefield surveillance.

Safe Pro’s AI is already integrated with Amazon Web Services (“AWS”) to support a scalable cloud-based solution. It also offers an on-the-edge variant, SpotlightAI(TM) OnSite, for real-time deployments in the field.

“Building upon our deployments in Ukraine we are hyper-focused on supporting the U.S. Army with cutting-edge, real-time threat detection capabilities,” said Dan Erdberg, chairman and CEO of Safe Pro Group. “We are proving in real-world operations that our novel battle tested AI for small object detection can enhance existing and future drone platforms, better enabling them to address the challenges of modern force protection.”

In addition to its existing deployment record, Safe Pro is targeting deeper alignment with the U.S. Department of Defense. The company is actively working to integrate its detection capabilities into the U.S. Army’s ATAK (Android Tactical Assault Kit) platform, software widely used by soldiers to share intelligence across connected mobile devices.

This move positions Safe Pro to take advantage of rising U.S. defense spending, particularly in the areas of drone technology and AI integration. Following the passage of the OBBBA, a legislative package allocating up to $30 billion in direct funding for drone and AI-related programs, Safe Pro is well-placed to compete for federal contracts and subcontracts tied to the broader modernization of the U.S. military’s tech stack.

The company’s announcement comes at a time of renewed emphasis on domestic drone production and AI development, reinforced by a July 2025 memorandum from Secretary of Defense Pete Hegseth calling for accelerated deployment of U.S.-developed drone and AI technologies.

Although Safe Pro’s recent momentum is tied closely to military applications, its AI detection platform has potential utility in humanitarian and commercial demining operations, including post-conflict reconstruction zones and infrastructure planning. Its ability to produce interactive 3D threat maps from drone imagery, coupled with GPS-tagged geospatial data, gives it an edge in environments where terrain complexity or limited visibility hinders manual detection methods. This makes it suitable for international NGOs and demining agencies working in heavily contaminated regions.

Beyond its SPOTD software, Safe Pro Group also offers Airborne Response drone-based services and Safe-Pro USA protective gear. These platforms are designed to complement one another, supporting a broader vision for integrated AI and drone-based security solutions across defense and civil sectors.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• PowerBank Corporation, a leading North American energy infrastructure developer and asset owner, has just begun installation of a 4.99 MW battery energy storage system (“BESS”) at its SFF-06 project in Cramahe, Ontario
• Once completed, this project is designed to deliver 4.75 MW of daily contract capacity for 251 business days annually, thereby powering Ontario’s grid with reliable, clean energy
• This ambitious project marks PowerBank’s bold entry into the battery storage market, a market that is projected to hit $31.2 billion by 2029, representing a 16.3% CAGR
• For the power supplied, PowerBank will receive a fixed capacity payment of $1,221/MW per business day, well above the $876/MW average for storage projects

Disseminated on behalf of PowerBank Corporation

PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103), a leading North American energy infrastructure developer and asset owner, just marked its entry into the rapidly growing Battery Energy Storage System (“BESS”) market with the installation of a BESS at its SFF-06 flagship project in Cramahe, Ontario. The project, once completed, will have a 4.99 MW capacity, delivering 4.74 MW of daily contract capacity for 251 business days annually, ultimately powering Ontario’s grid with reliable, clean energy (https://ibn.fm/3KhG2).

This ambitious project is backed by a $25.8 million loan from Royal Bank of Canada (“RBC”), with the institution serving as Lender, Administrative and Collateral Agent, and Green Loan Structuring Agent. This, coupled with the long-term value that is the 22-year contract that PowerBank entered with the Independent Electricity System Operator (“IESO”), has bolstered the project’s viability, particularly given that it will receive a fixed capacity payment of $1,221/MW per business day, well above the $876/MW average for storage projects.

According to Fortune Business Insights, the battery storage market is projected to hit a $31.2 billion valuation by 2029, representing a 16.3% CAGR. PowerBank is positioning itself for this growth, not just with strategic acquisitions, but also with calculated investments that will stamp its position as a leader in the industry. For the Ontario project, once completed, it will transform the city’s energy landscape, blending cutting-edge technology and sustainable investment (https://ibn.fm/Tz8Pb).

The first five of nine EVLO Battery containers are already on-site, with the remaining containers expected to be delivered and installed in the next few weeks or months. PowerBank’s management is optimistic that the investment will yield significant returns in the long run. In addition, it noted that the project itself aligns with PowerBank’s mission to accelerate renewable energy adoption through strategic government incentives such as the Clean Technology Investment Tax Credit, offering up to 30% reimbursements for eligible capital costs.

For more information, visit the company’s website at www.PowerBankCorp.com.

This report contains forward-looking information. Please refer to the press release entitled “PowerBank (SUUN) Begins Installation of First Battery Energy Storage System in Ontario” and dated August 6, 2025, for additional details on the information, risks, and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Ricin toxin is a potent biothreat, so lethal that even a dose the size of a grain of salt can be fatal within 48 to 72 hours.
• RiVax(R) is a subunit protein vaccine that incorporates Soligenix’s ThermoVax(R) technology, which eliminates the need for cold-chain storage. 
• Soligenix reports that the RiVax antigen has been shown to be safe in phase 1 studies in humans, with future steps including pivotal animal efficacy studies.

With global security threats driving demand for advanced biodefense solutions, Soligenix (NASDAQ: SNGX) is advancing RiVax(R), a heat-stable recombinant vaccine candidate aimed at protecting against deadly ricin toxin exposure. Supported by proprietary stabilization technology and robust preclinical data demonstrating long-lasting immunity, SNGX’s RiVax represents both a critical public safety innovation and a significant market opportunity in the specialized vaccine sector.

Ricin toxin, derived from castor beans, is a potent biothreat, so lethal that even a dose the size of a grain of salt can be fatal within 48 to 72 hours, depending on the route of exposure (https://ibn.fm/H5pl6). RiVax is a subunit protein vaccine composed of a genetically inactivated version of the ricin A-chain (“RTA”) with two mutations that nullify toxicity while preserving immunogenicity (https://ibn.fm/15PuI).

The vaccine incorporates Soligenix’s ThermoVax(R) formulation, thermostabilized platform that eliminates the need for cold-chain storage. This means RiVax, can remain stable and effective for at least a year even when stored at high temperatures such as 40°C (104°F), making it highly practical for stockpiling and deployment in remote or resource-limited settings.

Clinical evaluations have shown safety and immune response in humans. In phase 1A trials without adjuvant, RiVax demonstrated dose-dependent seroconversion and no toxicity up to 127 days post-vaccination. A follow-up Phase 1B trial formulated with adjuvant revealed an enhanced immunogenic profile, where the adjuvanted version elicited higher and more durable neutralizing antibody levels in human volunteers, along with a favorable safety profile (https://ibn.fm/zgbEL).

The company plans on pursuing approval for RiVax under the Animal Rule, noting that work to date has “focused on improving manufacturing processes and identifying correlates of immune protection that can demonstrate that protection observed in animals is likely to translate to humans” (https://ibn.fm/qJtbv). Soligenix reports that the RiVax antigen has been shown to be safe in two phase 1 studies in humans, with future steps including pivotal animal efficacy studies to demonstrate potency in animals, as well as a phase 2 clinical study in humans to confirm safety and correlate immune markers of protection with outcomes from animal studies.

The efficacy of RiVax in animal models has been especially noteworthy. Soligenix reported statistical protection of up to 100% in mice and nonhuman primates exposed to lethal doses of ricin via injection or aerosol, all with no signs of lung damage. Remarkably, a prime-boost regimen with two doses protected mice against ricin challenge equivalent to 10 times the lethal dose, maintaining immunity for at least one year. Further, correlates of protection identified in nonhuman primates versus humans bolster the case for efficacy under the FDA’s Animal Rule, enabling the company to advance RiVax under regulatory pathways designed for ethical and rare exposures (https://ibn.fm/MNErD).

RiVax has been granted both Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration, as well as Orphan status in Europe. If approved, the treatment may be eligible for a biodefense Priority Review Voucher (“PRV”), a potentially valuable incentive that offers transferable market value. The program’s development is backed by nondilutive funding, more than $40 million to date, from institutions including the National Institute of Allergy and Infectious Diseases (“NIAID”), reflecting federal support for biodefense countermeasures.

RiVax was originally licensed from researchers at UT Southwestern, and Soligenix holds a U.S. patent covering RiVax(R) as well as other biothreat antigens such as anthrax as well as multivalent compositions for filovirus infections like ebola, highlighting the vaccine candidates’ versatility in broader defense and public health strategies.  The company is also exploring potential inclusion in the U.S. Strategic National Stockpile and further formulation for biodefense readiness.

RiVax represents a strategic combination of innovative science, practical formulation and strong preclinical and early clinical validation. Its unique approach — leveraging thermostability, clear safety and durable, and broad-spectrum protection — sets a new standard for biodefense vaccines. For Soligenix, RiVax embodies the company’s commitment to address critical public health threats with advanced solutions. As Soligenix continues to advance this vaccine through pivotal trials, RiVax stands as a milestone in preparedness against ricin toxin and potentially other biothreats.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Bolivia, despite its rich mining history, remains one of the most underexplored silver jurisdictions due to a slow permitting process, but investors may benefit from dramatic upside if reforms advance.
• New Pacific Metals holds two of the most promising undeveloped silver projects globally in the country: Silver Sand and Carangas.
• Together, the two projects could position New Pacific among the top global primary silver producers, with potential combined output of nearly 19 million ounces annually when production begins.
• Backing from mining companies Silvercorp and Pan American Silver signals confidence in long-term development.

As global demand for silver intensifies, largely fueled by industrial applications such as solar panels and electric vehicles, supply remains constrained. Few new primary silver projects are advancing, leaving producers searching for untapped potential. For New Pacific Metals (NYSE American: NEWP) (TSX: NUAG), a Canadian exploration and development company, that opportunity lies in Bolivia, a country with deep silver reserves, but limited modern development.

Bolivia is geologically rich, with a long and significant silver history, but is currently underexplored. Due to a decade of slow-moving regulatory frameworks and limited foreign investment, the country has lagged behind more active mining jurisdictions. Still, there is growing recognition within Bolivia of the need to attract external capital to reignite its mining sector. With fiscal deficit hovering around 10% in recent years, foreign direct investment is increasingly seen as a way to strengthen the economy. This environment may mark a potential turning point for companies willing to operate in a higher-risk jurisdiction with significant untapped geological potential.

New Pacific Metals has positioned itself as a first mover in this environment. The company’s flagship Silver Sand project is among the most advanced silver developments in Bolivia. A preliminary feasibility study released in June 2024 outlines a 13-year mine life producing 12 million ounces of silver annually, 15 million ounces in the initial years. The economics are robust: at a silver price of US$24 per ounce, the project yields a post-tax NPV of US$740 million and a 37% IRR, with an all-in sustaining cost (“AISC”) of just US$10.69 per ounce. Payback is expected in under two years.

Meanwhile, the company’s second project, Carangas, expands its silver footprint even further. A preliminary economic assessment from September 2024 projects annual output of 6.6 million ounces of silver over a 16-year lifespan. Carangas also boasts favorable economics: US$501 million post-tax NPV, 26% IRR, and AISC of US$7.60, after accounting for lead and zinc by-product credits. Significantly, Carangas has over 1 million ounces of gold mineralization at depth, not yet factored into its economics, offering future upside.

Together, Silver Sand and Carangas could position New Pacific among the top global primary silver producers, with potential combined output of nearly 19 million ounces annually when production begins.

Bolivia presents challenges, with political uncertainty, regulatory delays, and untested permitting frameworks making project timelines less predictable. However, if the country could implement even modest reforms, the payoffs for early investors could be considerable.

Major shareholders see the same potential. New Pacific is 28% owned by Silvercorp Metals (NYSE-A: SVM) (TSX: SVM), a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability, and 13% owned by Pan American Silver (NYSE: PAAS) (TSX: PAAS), which describes itself as the world’s top silver producer. Their presence lends support and hints at possible strategic moves, either toward project development or future acquisition.

The market backdrop is also compelling. According to the World Silver Survey, industrial applications now account for 60% of annual silver demand (https://ibn.fm/167xP). As the transition to clean energy accelerates, the demand for silver in solar technology and battery applications is expected to rise, in addition to the growing appeal of silver as a bullion investment.

In spite of demands, few new high-grade, low-cost silver projects are coming online. That scarcity underscores the importance of projects like Silver Sand and Carangas. With promising geology, supportive shareholders, and improving local sentiment toward investment, New Pacific offers exposure to one of the last relatively untapped silver frontiers. Success will depend not just on ore grades or economics, but also on navigating Bolivia’s regulatory environment, yet the potential rewards are seen as significant.

For more information, visit the company’s website at www.NewPacificMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to NEWP are available in the company’s newsroom at https://ibn.fm/NEWP